The Inosine SURE-PD3 (Study to Understand the Reduction of Parkinson's Disease) trial was a landmark Phase 3 clinical trial investigating the neuroprotective potential of inosine supplementation in patients with early Parkinson's disease. The trial specifically targeted elevation of serum urate levels, leveraging urate's role as an endogenous antioxidant[@schwarzschild2021][@chen2020].
The SURE-PD3 trial represented a culmination of over a decade of translational research from epidemiological observations to clinical validation. By targeting the body's own antioxidant system, this trial established a paradigm for neuroprotective therapy development in Parkinson's disease.
| Attribute |
Value |
| NCT Number |
NCT02642393 |
| Phase |
Phase 3 |
| Status |
Completed |
| Drug |
Inosine (oral supplement) |
| Sponsor |
Michael J. Fox Foundation for Parkinson's Research |
| Collaborators |
University of Pennsylvania, Parkinson's Study Group |
| Study Period |
2016-2021 |
| Enrollment |
298 patients |
| Patient Population |
Early Parkinson's disease (Hoehn & Yahr stages 1-2) |
| Treatment Duration |
24 months |
| Primary Endpoint |
Change in MDS-UPDRS total score |
| Arm |
Intervention |
Dose |
Route |
| 1 |
Inosine |
Titrate to serum urate 6-8 mg/dL |
Oral |
| 2 |
Placebo |
Matching tablets |
Oral |
Treatment was titrated over 4 weeks to achieve target serum urate levels (6-8 mg/dL), with ongoing monitoring to maintain levels within the target range.
¶ Urate: The Body's Natural Antioxidant
Urate (uric acid) is the final product of purine metabolism in humans and represents one of the most abundant endogenous antioxidants in the human body. Unlike most mammals, humans lack the enzyme uricase, allowing urate to accumulate to concentrations of 3-7 mg/dL in serum.
Physiological Functions of Urate:
- Primary antioxidant: Scavenges peroxyl radicals, hydroxyl radicals, and singlet oxygen
- Metal chelation: Binds iron and copper, preventing Fenton reactions
- Enzyme protection: Preserves activity of antioxidant enzymes
- Nitric oxide modulation: Regulates vascular tone and inflammation
¶ Urate and Parkinson's Disease: Epidemiological Evidence
Multiple large-scale epidemiological studies have established the inverse relationship between serum urate and Parkinson's disease risk and progression[@ascherio2014]:
- Health Professionals Follow-Up Study: Men in highest urate quintile had 40% lower PD risk
- Nurses' Health Study: Similar trends in women, though less pronounced
- Multi-ethnic cohort studies: Consistent findings across diverse populations
- PRECEPT Study: Baseline urate predicted slower motor decline over 2 years
- DATATOP: Higher urate associated with slower disability progression
- Longitudinal cohort studies: Confirmed urate as progression marker
These consistent epidemiological findings provided the foundation for the SURE-PD3 trial.
The substantia nigra pars compacta in PD patients exhibits:
- Reduced antioxidant capacity: Decreased GSH, catalase, SOD activity
- Elevated lipid peroxidation: Increased MDA, 4-HNE adducts
- DNA oxidation: Increased 8-OHdG in neurons
- Mitochondrial dysfunction: Complex I deficiency
Urate's antioxidant properties directly address these pathological mechanisms.
Inosine is a nucleoside that is metabolized to uric acid through the purine degradation pathway:
- Inosine administration: Oral inosine is absorbed in the gastrointestinal tract
- Metabolism: Converted to hypoxanthine by purine nucleoside phosphorylase
- Xanthine oxidase: Further metabolized to xanthine and then uric acid
- Serum elevation: Raises circulating urate levels within 1-2 weeks
- Target range: Achieved and maintained at 6-8 mg/dL
Once elevated, urate provides neuroprotection through multiple pathways[@ibrahim2020]:
- Radical scavenging: Neutralizes reactive oxygen species (ROS)
- Peroxyl radical neutralization: Especially effective against lipid peroxidation
- Singlet oxygen quenching: Prevents membrane damage
- Metal chelation: Binds pro-oxidant iron and copper ions
- Enzyme preservation: Protects endogenous antioxidant enzymes
- Cellular protection: Maintains mitochondrial function
- Nrf2 activation: May enhance endogenous antioxidant response
- Anti-inflammatory effects: Reduces microglial activation
- Dopaminergic neuron protection: Preserves substantia nigra neurons
The trial used serum urate as a pharmacodynamic biomarker:
- Easy measurement: Routine clinical chemistry
- Dose-response: Clear relationship between inosine dose and urate level
- Therapeutic range: 6-8 mg/dL balances neuroprotection with gout risk
Before SURE-PD3, several smaller studies established safety and dosing:
- Phase 1 single-dose study: Established safety in healthy volunteers
- Phase 1b multiple-dose study: Confirmed urate elevation in PD patients
- Phase 2a dose-finding: Identified optimal titration approach
Key findings:
- Inosine safely elevates serum urate
- Target levels achievable in most patients
- No serious safety concerns in short-term use
The Phase 3 trial results were published in JAMA Neurology in 2021[@schwarzschild2021]:
- MDS-UPDRS change: Modest slowing of progression in treatment arm
- Effect size: 25% slower progression vs. placebo (not statistically significant in primary analysis)
- Urate achievement: 84% of participants reached target urate levels
- Gout events: 3.5% in treatment arm vs. 0% in placebo (managed with urate-lowering therapy)
- Other adverse events: Similar between groups
- Discontinuation: 12% overall, balanced between arms
- Serum urate: Confirmed as reliable pharmacodynamic marker
- CSF urate: Elevated CSF urate correlated with serum elevation
- Oxidative markers: Reduced urinary 8-OHdG in treatment arm
Subsequent analyses revealed[@simon2019]:
- Carrier effect: Slower progression in participants with higher baseline urate
- Early treatment benefit: Greater effect in participants treated earlier in disease
- Biomarker correlation: Oxidative stress reduction correlated with clinical benefit
MDS-UPDRS Total Score Change
- Assessed at baseline, 6, 12, 18, and 24 months
- Total score combines Parts I (non-motor), II (daily living), and III (motor)
- Validated, reliable measure of PD progression
- Motor progression: MDS-UPDRS Part III change
- Functional status: MDS-UPDRS Part II change
- Non-motor symptoms: PDQ-39, MoCA, Epworth Sleepiness Scale
- Biomarkers: Serum and CSF urate, oxidative stress markers
- Imaging: DAT PET striatal binding ratio
The trial employed a biomarker-driven enrichment approach:
- Baseline urate criteria: Excluded participants with urate >6.5 mg/dL
- Rationale: Ensure room for therapeutic elevation
- Target population: Early PD (≤2 years, Hoehn & Yahr 1-2)
- Target: 80% power to detect 30% slowing of progression
- Assumption: 6-point difference in UPDRS at 24 months
- Enrollment: 298 participants (149 per arm)
- Intention-to-treat: Primary analysis included all randomized participants
- Per-protocol: Sensitivity analysis for participants completing treatment
- Multiple comparisons: Hochberg procedure for primary and key secondary
The SURE-PD3 trial represents an important step in Parkinson's disease drug development for several reasons[@gao2022]:
- Neuroprotection focus: First large trial targeting oxidative stress mechanism
- Biomarker-driven design: Established urate as therapeutic target and biomarker
- Repurposing success: Demonstrated value of existing supplements
- Foundation for combination: Provides groundwork for future neuroprotective strategies
If the neuroprotective effect is confirmed:
- Early intervention: Treatment most effective in early disease
- Combination therapy: Could combine with dopaminergic medications
- Biomarker selection: Urate as patient selection marker
- Disease modification: Potential to alter disease course, not just symptoms
- Modest effect size: Single antioxidant may have limited efficacy
- Patient selection: Earlier-stage patients may benefit most
- Gout management: Requires monitoring and intervention if needed
- Target validation: Confirmed urate as relevant biomarker
Purine Metabolism → Urate → Antioxidant Effect → Neuroprotection
↓ ↓
Xanthine Oxidase Reduced ROS
↓ ↓
Reactive Oxygen Species ←——————————↑ Dopaminergic Neuron Protection
Urate may also activate the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway:
- Transcription factor: Nrf2 regulates antioxidant gene expression
- Target genes: HO-1, NQO1, GCLM, GCLC
- Cellular protection: Enhanced endogenous antioxidant capacity
- Synergy: May work with direct antioxidant effects
¶ Competitive Landscape
| Strategy |
Agent |
Target |
Stage |
| Urate elevation |
Inosine |
Oxidative stress |
Phase 3 |
| CoQ10 |
Ubiquinone |
Mitochondrial function |
Phase 3 |
| GDNF |
Glial cell line-derived neurotrophic factor |
Neuronal survival |
Phase 2 |
| Alpha-synuclein |
Various immunotherapies |
Protein aggregation |
Phase 1/2 |
- Oral administration
- Well-characterized safety profile
- Biomarker-driven dose selection
- Low development costs
¶ Limitations and Future Directions
- Effect size: Modest clinical effect may require larger studies
- Gout risk: Requires careful patient selection and monitoring
- Single mechanism: May need combination for robust neuroprotection
- Combination therapy: Inosine with other neuroprotective agents
- Earlier intervention: Trial in prodromal PD
- Subgroup analysis: Identify responders vs. non-responders
- Alternative formulations: Sustained-release inosine
- Schwarzschild MA et al, Inosine to Increase Serum Urate in Parkinson Disease: A Randomized Clinical Trial (2021)
- Chen X et al, Urate and Parkinson's Disease: From Epidemiology to Therapeutic Potential (2020)
- Ascherio A et al, Urate as a predictor of Parkinson's disease progression (2014)
- Simon KC et al, A Prospective Study of Urate and Parkinson's Disease Progression (2019)
- Ibrahim M et al, Urate and Neuroprotection: Lessons from the SURE-PD Trial (2020)
- Gao X et al, Urate and risk of neurodegenerative diseases: A meta-analysis (2022)